PBYI - Puma Biotechnology, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
39.13
-0.33 (-0.84%)
As of 2:38PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close39.46
Open39.54
Bid39.04 x 900
Ask39.12 x 1400
Day's Range38.78 - 39.88
52 Week Range17.60 - 71.70
Volume232,434
Avg. Volume1,125,404
Market Cap1.506B
Beta (3Y Monthly)1.15
PE Ratio (TTM)N/A
EPS (TTM)-2.99
Earnings DateMay 7, 2019 - May 13, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est43.88
Trade prices are not sourced from all markets
  • Puma Biotech's (PBYI) Nerlynx Gets Approval in Australia
    Zacks7 days ago

    Puma Biotech's (PBYI) Nerlynx Gets Approval in Australia

    Puma Biotech (PBYI) gains an approval in Australia for Nerlynx as an extended adjuvant treatment in adult patients with early stage HER2-positive breast cancer.

  • Markit7 days ago

    See what the IHS Markit Score report has to say about Puma Biotechnology Inc.

    Puma Biotechnology Inc NASDAQ/NGS:PBYIView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate and increasing Bearish sentimentShort interest | NegativeShort interest is moderately high for PBYI with between 10 and 15% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on March 15. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding PBYI are favorable, with net inflows of $3.71 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Why Edwards Lifesciences, Village Farms International, and Puma Biotechnology Jumped Today
    Motley Fool8 days ago

    Why Edwards Lifesciences, Village Farms International, and Puma Biotechnology Jumped Today

    Earnings momentum and some good business results sent these stocks up.

  • Business Wire8 days ago

    Puma Biotechnology’s Licensing Partner Specialised Therapeutics Asia Receives Regulatory Approval to Commercialize NERLYNX® (neratinib) for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer

    LOS ANGELES-- -- Neratinib becomes the first anti-HER2 treatment to be approved in Australia, as extended adjuvant therapy for early stage HER2-positive breast cancer following adjuvant trastuzumab-based therapy. Treatment with neratinib in the approved indication resulted in a 34% reduction in the risk of invasive disease recurrence or death versus placebo after patients completed one year of therapy ...

  • Thomson Reuters StreetEvents12 days ago

    Edited Transcript of PBYI earnings conference call or presentation 28-Feb-19 9:30pm GMT

    Q4 2018 Puma Biotechnology Inc Earnings Call

  • Business Wire12 days ago

    Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

    Puma Biotechnology, Inc. (PBYI), a biopharmaceutical company, announced that on March 12, 2019 the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 30,688 shares of Puma common stock to five new non-executive employees. The awards were granted under Puma’s 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The awards were granted as an inducement material to the new employees entering into employment with Puma, in accordance with Nasdaq Listing Rule 5635(c)(4).

  • Puma Biotech (PBYI) Up More Than 95% in 3 Months: Here's Why
    Zacks12 days ago

    Puma Biotech (PBYI) Up More Than 95% in 3 Months: Here's Why

    Sales of Puma Biotech's (PBYI) only marketed drug Nerlynx are impressive in Q4, improving from third-quarter 2018 levels.

  • Will Puma Biotechnology Continue to Surge Higher?
    Zacks18 days ago

    Will Puma Biotechnology Continue to Surge Higher?

    As of late, it has definitely been a great time to be an investor in Puma Biotechnology.

  • Business Wire21 days ago

    Puma Biotechnology to Present at Cowen’s Annual Health Care Conference

    Puma Biotechnology, Inc. , a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 10:00 a.m.

  • Implied Volatility Surging for Puma Biotechnology (PBYI) Stock Options
    Zacks21 days ago

    Implied Volatility Surging for Puma Biotechnology (PBYI) Stock Options

    Investors need to pay close attention to Puma Biotechnology (PBYI) stock based on the movements in the options market lately.

  • 3 Takeaways from Puma Biotechnology's 2018 Earnings
    Motley Fool22 days ago

    3 Takeaways from Puma Biotechnology's 2018 Earnings

    The pharmaceutical company may have proved Wall Street wrong, but it has a long way to go to reach its full potential -- and that's a good thing for investors.

  • GlobeNewswire22 days ago

    Recent Analysis Shows Altria Group, Puma Biotechnology, Tanger Factory Outlet Centers, PTC, Aptiv, and Olin Market Influences — Renewed Outlook, Key Drivers of Growth

    NEW YORK, March 04, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Puma Biotechnology Earnings: PBYI Stock Skyrockets on Q4 Results
    InvestorPlace25 days ago

    Puma Biotechnology Earnings: PBYI Stock Skyrockets on Q4 Results

    Puma Biotechnology earnings for the fourth quarter of 2018 have PBYI stock soaring on Friday.Source: Shutterstock Puma Biotechnology (NASDAQ:PBYI) reported losses per share of 32 cents for the fourth quarter of the year. This is better than the company's losses per share of $1.03 from the same period of the year prior. It was also a major boon to PBYI stock by beating out Wall Street's losses per share estimate of 77 cents for the quarter.Net loss reported by Puma Biotechnology for the fourth quarter of 2018 was $30.70 million. This is a narrower net loss than the company's $64.10 million that was reported in the fourth quarter of 2017.InvestorPlace - Stock Market News, Stock Advice & Trading TipsOperating loss reported by Puma Biotechnology for the fourth quarter of the year comes in at $18.60 million. The pharmaceutical company reported an operating loss of $63.60 million during the same time last year.Puma Biotechnology earnings for the fourth quarter of 2018 also includes revenue of $71.10 million. This is a massive increase over the company's revenue of $21.60 million for the fourth quarter of the previous year. It is also a blessing to PBYI sock by coming in above analysts' revenue estimate of $53.50 million for the period. * 9 Best Stocks to Buy on U.S.-China Trade Optimism The strong revenue growth in the Puma Biotechnology earnings report fourth quarter of the year is due to Nerlynx sales. This is the company's first commercial product. Its sales account for $61.10 million of the company's revenue during the quarter.PBYI stock was up 41% as of noon Friday. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Reasons Kraft Heinz Stock Is a Contrarian Buy * 5 Housing Stocks to Buy for Renewed Homebuilder Confidence * 7 of the Best ETFs to Buy for a Rock-Solid Portfolio As of this writing, William White did not hold a position in any of the aforementioned securities.Compare Brokers The post Puma Biotechnology Earnings: PBYI Stock Skyrockets on Q4 Results appeared first on InvestorPlace.

  • Benzinga25 days ago

    Cantor Fitzgerald Bumps Puma Biotechnology Price Target On Strong Nerlynx Sales

    Puma Biotechnology Inc (NASDAQ: PBYI ) announced fourth-quarter results and 2019 guidance Thursday that were ahead of expectations, boosting confidence in Nerlynx achieving a global product revenue estimate ...

  • Here's Why Puma Biotechnology Is Soaring Today
    Motley Fool25 days ago

    Here's Why Puma Biotechnology Is Soaring Today

    The company announced fourth-quarter and full-year 2018 earnings.

  • Puma Biotech (PBYI) Q4 Loss Narrows, Nerlynx Pulls Stock Up
    Zacks25 days ago

    Puma Biotech (PBYI) Q4 Loss Narrows, Nerlynx Pulls Stock Up

    Puma Biotech (PBYI) betters loss estimates in Q4 and also rides high on revenue beat. Nerlynx impresses with strong sequential and year-over-year growth.

  • Benzinga25 days ago

    The Daily Biotech Pulse: Puma Biotech Earnings, Mersana Offering, Orphan Drug Designation For Ascendis

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 28) Amphastar Pharmaceuticals Inc (NASDAQ: AMPH ) Abbott ...

  • Puma Biotechnology Inc (PBYI) Q4 2018 Earnings Conference Call Transcript
    Motley Fool26 days ago

    Puma Biotechnology Inc (PBYI) Q4 2018 Earnings Conference Call Transcript

    PBYI earnings call for the period ending December 31, 2018.

  • Business Wire26 days ago

    Puma Biotechnology Reports Fourth Quarter and Full Year 2018 Financial Results

    Puma Biotechnology, Inc. , a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2018. Unless otherwise stated, all comparisons are for the fourth quarter and full year 2018, compared to the fourth quarter and full year 2017.

  • Benzinga26 days ago

    Puma Biotechnology Q4 Earnings Preview

    Puma Biotechnology (NYSE: PBYI ) will be releasing its next round of earnings this Thursday, Feb. 28. For all of the relevant information, here is your guide for Thursday's Q4 earnings announcement. Earnings ...

  • GlobeNewswire26 days ago

    Predictive Technology Group Names Jay M. Moyes to Its Board of Directors

    Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent therapeutic intervention through precision therapeutic treatments, announces that Jay M. Moyes has been named to the company’s Board as an independent director, effective immediately. Moyes brings more than 30 years of healthcare industry expertise in senior-level financial positions and has significant governance experience from Board memberships at publicly traded healthcare companies. “We are delighted to attract a professional of Jay’s caliber as we build out Predictive’s Board with proven leaders to support our strategy of bringing proprietary genetic-based diagnostics and therapeutics to market,” said Bradley C. Robinson, CEO of Predictive Technology Group.

  • Celcuity Inc. (CELC) Q4 2018 Earnings Conference Call Transcript
    Motley Fool28 days ago

    Celcuity Inc. (CELC) Q4 2018 Earnings Conference Call Transcript

    CELC earnings call for the period ending December 31, 2018.